Mircera Европейски съюз - български - EMA (European Medicines Agency)

mircera

roche registration gmbh - Метокси полиетилен гликол-эпоэтин бета - anemia; kidney failure, chronic - Антианемични препарати - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

Activyl Европейски съюз - български - EMA (European Medicines Agency)

activyl

intervet international bv - индоксакарб - ectoparasiticides за външно приложение, включително. инсектициди, indoxacarb - dogs; cats - Лечение и предотвратяване на инфекция с бълхи. За кучета и котки: Лечение и профилактика на заразяване с бълхи. Ветеринарният лекарствен продукт може да бъде използван като част от терапевтична стратегия за алергичен дерматит против бълхи. Развитието на стадиите на бълхи в непосредствената околна среда на домашния любимец се убива след контакт с животни, третирани с activyl.

ProMeris Duo Европейски съюз - български - EMA (European Medicines Agency)

promeris duo

pfizer limited  - metaflumizone, amitraz - ectoparasiticides за външно приложение, включително. инсектициди - Кучета - За лечение и предотвратяване на заразяване с бълхи (ctenocephalides canis и с. фелиз) и кърлежи (Иксодовые рициново, кърлежи ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus и dermacentor variabilis), и лечение demodectic краста (причинена от Демодекозом). ) и въшки (trichodectes канис) при кучета. Ветеринарният лекарствен продукт може да бъде използван като част от терапевтичната стратегия за алергичен дерматит при бълхи (fad).

Activyl Tick Plus Европейски съюз - български - EMA (European Medicines Agency)

activyl tick plus

intervet international bv - indoxacarb, permethrin - перметрин, комбинации, ectoparasiticides за външно приложение, включително. инсектициди - Кучета - Лечение на инфестации с бълхи (ctenocephalides felis); продуктът има устойчива инсектицидна ефикасност до 4 седмици срещу ctenocephalides felis. Продуктът има устойчива акарицидна ефикасност до 5 седмици срещу ixodes ricinus и до 3 седмици срещу rhipicephalus sanguineus. Едно лечение осигурява репелентна (анти-хранеща) активност срещу пясъчни мухи (phlebotomus perniciosus) за период до 3 седмици.

KETAMIN 10 % България - български - БАБХ (Българска агенция по безопасност на храните)

ketamin 10 %

bremer pharma gmbh - Кетамин хидрохлорид - инжекционен разтвор - 115, 34 mg/ml (еквивалент на ketamine 100 mg) - котки, кучета

Opdivo Европейски съюз - български - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Ryzodeg Европейски съюз - български - EMA (European Medicines Agency)

ryzodeg

novo nordisk a/s - инсулин аспарт, инсулин degludec - Захарен диабет - Лекарства, използвани при диабет - Лечение на захарен диабет при възрастни, юноши и деца на възраст над 2 години.